Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection

Inclusion Criteria: * 1\. Aged between 18 and 75 years, extremes included, male or female * 2\. Laboratory (RT-PCR) and clinical symptoms confirmed case of 2019-nCoV pneumonia, according to the official guideline "Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 5)" * 3\. Hospitalised with a new onset respiratory illness (≤7 days since illness onset) * 4\. No family planning within six months, and agree to take effective contraceptive measures throughout the study and for at least 30 days after the final study drug dose * 5\. Must agree not to enroll in another study of an investigational agent prior to completion of Day 30 of study * 6\. Informed Consent Form (ICF) signed voluntarily Exclusion Criteria: * 1\. Severe 2019-nCoV pneumonia met one of the following criteria: respiratory distress, RR ≥ 30 times / min, or SaO2 / SpO2 ≤ 93% in resting state, or arterial partial pressure of oxygen (PaO2) /concentration of oxygen (FiO2) ≤ 300mmHg (1mmHg = 0.133kpa) * 2\. Critical severe 2019-nCoV pneumonia met one of the following criteria: respiratory failure and mechanical ventilation required, or shock, or combined with other organ failure required ICU monitoring treatment * 3\. Severe liver disease (e.g. Child Pugh score ≥ C, AST \> 5 times upper limit) * 4\. Known allergic reaction to any of components of ASC09 / ritonavir compound tablets * 5\. Patients with definite contraindications in the label of ritonavir * 6\. Positive serum pregnancy test result for women with childbearing potential at screening * 7\. Using HIV protease inhibitor drugs * 8\. Not suitable for the study, in the opinion of the Investigator (e.g. patient may be transferred to another hospital during the study period, patient with multiple basic diseases, etc.)